103 related articles for article (PubMed ID: 22986736)
1. More about imatinib and nilotinib combination therapy in chronic myeloid leukemia.
Gómez-Almaguer D; Tarín-Arzaga L; Cantú-Rodríguez O; Ceballos-López A
Acta Haematol; 2013; 129(1):18-9. PubMed ID: 22986736
[No Abstract] [Full Text] [Related]
2. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
[No Abstract] [Full Text] [Related]
3. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
5. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Breccia M; Santopietro M; Cannella L; Federico V; Loglisci G; Serrao A; Petrucci L; Salaroli A; Nanni M; De Propris MS; Diverio D; Alimena G
Leuk Res; 2011 Jun; 35(6):e91-2. PubMed ID: 21316103
[No Abstract] [Full Text] [Related]
6. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
7. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
[No Abstract] [Full Text] [Related]
8. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
[No Abstract] [Full Text] [Related]
9. Doctors condemn NICE's guidance on leukaemia drug.
Mayor S
BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
[No Abstract] [Full Text] [Related]
10. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
11. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
13. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
14. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Silver RT; Cortes J; Waltzman R; Mone M; Kantarjian H
Haematologica; 2009 May; 94(5):743-4. PubMed ID: 19407320
[No Abstract] [Full Text] [Related]
15. Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.
Alimena G; Breccia M; Mancini M; Diverio D; Nanni M; De Propris MS; Cimino G; Pane F; Mandelli F
Leukemia; 2005 Feb; 19(2):287-9. PubMed ID: 15538403
[No Abstract] [Full Text] [Related]
16. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Fang B; Li N; Song Y; Han Q; Zhao RC
Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
[No Abstract] [Full Text] [Related]
18. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
19. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]